|
|
|
|
 Dr Hakan Sakul,
Senior Director and Global Head of Diagnostics Pfizer Global R&D Hakan is a Senior Director in the Molecular Medicine Group where he serves as the Global Head of Diagnostics and Oncology Leads, leading Pfizer’s Diagnostics efforts across its pharmaceutical portfolio, as well as specific coverage of Oncology programs for Companion Diagnostics and related technologies. A native of Turkey, Hakan received his BS and MS degrees from Ankara University in Turkey. Hakan was a recipient of the “Freedom from Hunger” Scholarship from The Rotary Foundation in its inaugural year in 1986, and completed his PhD degree in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar in 1990. He then completed a postdoctoral program at the University of California-Davis. After spending 4 years in the biotech industry working in human genetics, pharmacogenomics and statistical genetics, Hakan joined Parke-Davis Pharmaceuticals – Warner Lambert as Director of Human Genetics, Statistical Genetics and Pharmacogenetics programs. Due to site closure following Pfizer’s merger with Warner-Lambert, he moved to Ardais Corporation in Boston, Massachusetts as Vice President of Statistical Genomics. At the end of 2001, he returned to Pfizer as Director and Site Head for Clinical Pharmacogenomics in Groton/New London Laboratories, with responsibilities across all therapeutic areas. Hakan was promoted to Senior Director in mid-2005 and assumed his current role mid-2007. A member of the Editorial Board of the Personalized Medicine Journal, the Organizing Committee of the annual Personalized Medicine meeting at Harvard, and the author of over 30 scientific refereed articles and several book chapters, Hakan has served as an invited speaker on many panel discussions and scientific meetings. His external representation of Pfizer includes memberships on the Clinical Science and Technology Committee of The Personalized Medicine Coalition, the Research Tools and Molecular Diagnostics Sub Team of BIO, and the California Healthcare Institute Diagnostics Working Group. Hakan is keenly interested in applications of companion diagnostics, pharmacogenomics and related technologies to the pharmaceutical pipeline to advance Personalized Medicine for the improvement of individualized healthcare.Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 9.40am Case study: teaming up for the development of a companion diagnostic for crizotinib (PF-02341066)
- Shifting the focus toward diagnostic co-development: motivation, strategy and challenges
- Respective goals for PF-02341066 development and application and the Abbott test
- Update on process – what has been learned thus far with regard to co-development of therapy and diagnostics
Dr Hakan Sakul, Senior Director and Global Head of Diagnostics,
Pfizer Global R&D 10.30am Panel discussion: strategies for development, approval and reimbursement of cancer diagnostics in conjunction with targeted therapies
- The challenge: both the diagnostic and the drug must be approved and reimbursed.
- Considering the options for pharma companies in diagnostic development – internal development, external partnerships or outsourcing?#
- Strategies for overcoming regulatory and reimbursement concerns – who needs to make the initial investment? What are the regulatory considerations? Who ultimately pays for a diagnostic test?
Vice President Pharma Business Development,
QIAGEN President Molecular Diagnostics,
Abbott Molecular Dr Hakan Sakul, Senior Director and Global Head of Diagnostics,
Pfizer Global R&D Vice President Scientific and Medical Affairs,
Veridex (a Johnson & Johnson compnay) |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
